1. Biological Therapy in Psoriasis: Recognizing the Value

3. Program Objectives

4. Effects of Stigmatization

5. Psoriasis Has a Significant Impact on Major Life-Changing Decisions

6. Five Key Components to CLCI

7. DLQI

8. Coping Strategies Mediate the Effects of Psoriasis

9. Current Treatment Use With Moderate to Severe Psoriasis

10. Psoriasis and Sexual Behavior

11. Psoriasis and QoL

12. Challenges With Assessing the Impact of Psoriasis on QoL

13. PROs

14. Characterizing Psoriasis From the Patient’s Perspective

15. PSI

16. PSI Total Score

17. SAPS

18. Relief From Itching, Scaling and Pain With Biologics as Measured by the PSD

19. Itch and Psoriasis Treatment

20. PROs: Summary

21. Recommendations for Evaluating QoL in Practice

22. PASI-90 Is Associated With Improved DLQI Outcome

23. ERASURE/FIXTURE: Psoriasis Skin Clearance is Associated With Patient-Reported Impact

24. Higher PASI Responses Lead to Greater Improvements in QoL

25. PASI-90 Is Associated With Improved DLQI Outcome

26. Absolute PASI Values (Cutoffs: 5, 3, or 2) Might Provide a Better Benchmark

27. Higher PASI Responses Lead to Greater Improvements in Quality of Life

28. Results on PASI for Secukinumab 300 mg

29. Conclusion

30. Abbreviations

31. Abbreviations (cont)

32. Abbreviations (cont)